StockData
Oculis Holding AG logo

Oculis Holding AG (OCS) stock

OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 4, 2026Score 1/30
$7.64+0.14 (+1.87%)

Close on Nov 13, 2026Market cap $459.08MP/E –Yield –

Earnings

Oculis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Oculis's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Oculis has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Oculis puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Oculis filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?